SCHEMBL1643402

SCHEMBL1643402

COc1c(-c2ccccc2)cccc1C(c1ccccc1)c1cccc(-c2ccccc2)c1O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 6/20 0.49
PDE4A P27815 5/20 0.49
PDE4C Q08493 5/20 0.49
PDE4D Q08499 5/20 0.49
HNF4A P41235 1/20 0.37
HDAC4 P56524 2/20 0.37
HDAC2 Q92769 2/20 0.37
HDAC8 Q9BY41 2/20 0.37
BACE1 P56817 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
NR1H4 Q96RI1 1/20 0.35
PTPN5 P54829 1/20 0.34
ALOX5AP P20292 1/20 0.34
FEN1 P39748 1/20 0.34
F2 P00734 1/20 0.34
F10 P00742 1/20 0.34
PLG P00747 1/20 0.34
PLAU P00749 1/20 0.34
PLAT P00750 1/20 0.34
PRSS1 P07477 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1642694 0.87 PDE4B (0.42) PDE4BPDE4APDE4CPDE4DBACE1
SCHEMBL1639130 0.87 PDE4B (0.42) PDE4BPDE4APDE4CPDE4DHNF4A
SCHEMBL1642703 0.82 PDE4B (0.51) PDE4BPDE4APDE4CPDE4DHNF4A
SCHEMBL12726015 0.81 ACP3 (0.41) PDE4BPDE4APDE4CPDE4DHNF4A
SCHEMBL12776587 0.77 PDE4B (0.38) PDE4BPDE4APDE4CPDE4DHDAC4
SCHEMBL617346 0.75 PDE4B (0.43) PDE4BPDE4APDE4CPDE4DNR1H4
SCHEMBL1638873 0.75 IDO1 (0.44) HDAC4HDAC2HDAC8ALDH1A1HPGD
SCHEMBL13385087 0.72 PDE4B (0.48) PDE4BPDE4APDE4CPDE4DNR1H4
SCHEMBL12646977 0.72 PDE4B (0.45) PDE4BPDE4APDE4CPDE4DHNF4A
SCHEMBL27890122 0.71 PDE4B (0.55) PDE4BPDE4APDE4CPDE4DBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8557936-B2 Catalyst compounds and use thereof EXXONMOBIL CHEMICAL PATENTS INC. (US) 2013-10-15 US disclosed
US-8557936-B2 Catalyst compounds and use thereof EXXONMOBIL CHEMICAL PATENTS INC. (US) 2013-10-15 US disclosed
US-8557936-B2 Catalyst compounds and use thereof EXXONMOBIL CHEMICAL PATENTS INC. (US) 2013-10-15 US disclosed
EP-2493934-A2 CATALYST COMPOUNDS AND USE THEREOF ExxonMobil Chemical Patents Inc. (US) 2012-09-05 EP disclosed
WO-2011056428-A2 CATALYST COMPOUNDS AND USE THEREOF EXXONMOBIL CHEMICAL PATENTS INC. (US) 2011-05-12 WO disclosed
WO-2011056428-A2 CATALYST COMPOUNDS AND USE THEREOF EXXONMOBIL CHEMICAL PATENTS INC. (US) 2011-05-12 WO disclosed
US-20110098425-A1 Catalyst Compounds and Use Thereof EXXONMOBIL CHEMICAL PATENTS INC. 2011-04-28 US disclosed
US-20110098425-A1 Catalyst Compounds and Use Thereof EXXONMOBIL CHEMICAL PATENTS INC. 2011-04-28 US disclosed
US-20110098425-A1 Catalyst Compounds and Use Thereof EXXONMOBIL CHEMICAL PATENTS INC. 2011-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098425-A1 Catalyst Compounds and Use Thereof ALOX12, THEM6, ALOX15 PDE4B 4472/4885PDE4A 4587/4885PDE4C 4676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.